Radiotherapy quality assurance report from Children's Oncology Group AHOD0031 Journal Article


Authors: Dharmarajan, K. V.; Friedman, D. L.; FitzGerald, T. J.; McCarten, K. M.; Constine, L. S.; Chen, L.; Kessel, S. K.; Iandoli, M.; Laurie, F.; Schwartz, C. L.; Wolden, S. L.
Article Title: Radiotherapy quality assurance report from Children's Oncology Group AHOD0031
Abstract: Purpose A phase 3 trial assessing response-based therapy in intermediate-risk Hodgkin lymphoma mandated real-time central review of involved field radiation therapy (IFRT) and imaging records by a centralized review center to maximize protocol compliance. We report the impact of centralized radiation therapy review on protocol compliance. Methods and Materials Review of simulation films, port films, and dosimetry records was required before and after treatment. Records were reviewed by study-affiliated or review center-affiliated radiation oncologists. A deviation of 6% to 10% from protocol-specified dose was scored as "minor"; a deviation of >10% was "major." A volume deviation was scored as "minor" if margins were less than specified or "major" if fields transected disease-bearing areas. Interventional review and final compliance review scores were assigned to each radiation therapy case and compared. Results Of 1712 patients enrolled, 1173 underwent IFRT at 256 institutions in 7 countries. An interventional review was performed in 88% of patients and a final review in 98%. Overall, minor and major deviations were found in 12% and 6% of patients, respectively. Among the cases for which ≥1 pre-IFRT modification was requested by the Quality Assurance Review Center and subsequently made by the treating institution, 100% were made compliant on final review. By contrast, among the cases for which ≥1 modification was requested but not made by the treating institution, 10% were deemed compliant on final review. Conclusions In a large trial with complex treatment pathways and heterogeneous radiation therapy fields, central review was performed in a large percentage of cases before IFRT and identified frequent potential deviations in a timely manner. When suggested modifications were performed by the institutions, deviations were almost eliminated. © 2015 Elsevier Inc.
Keywords: adolescent; adult; child; controlled study; treatment response; major clinical study; prednisone; cancer localization; cancer recurrence; cisplatin; doxorubicin; cancer combination chemotherapy; cancer patient; cancer radiotherapy; cytarabine; cancer staging; outcome assessment; positron emission tomography; follow up; lymph node metastasis; quality control; computer assisted tomography; multiple cycle treatment; etoposide; radiotherapy; cyclophosphamide; dexamethasone; vincristine; medical record review; oncology; childhood cancer; hodgkin disease; risk assessment; intervention study; infant; dosimetry; quality assurance; newborn; cancer size; fluorodeoxyglucose f 18; patient compliance; bleomycin; scintigraphy; radiation oncologists; after-treatment; randomized controlled trial (topic); phase 3 clinical trial (topic); gallium; multicenter study (topic); protocol compliance; real time; films; involved-field radiation therapy; involved field radiation therapy; intermediate risks; methods and materials; human; priority journal; article; radiation oncologist; interventional; volume deviations
Journal Title: International Journal of Radiation Oncology, Biology, Physics
Volume: 91
Issue: 5
ISSN: 0360-3016
Publisher: Elsevier Inc.  
Date Published: 2015-04-01
Start Page: 1065
End Page: 1071
Language: English
DOI: 10.1016/j.ijrobp.2014.11.034
PROVIDER: scopus
PUBMED: 25670539
PMCID: PMC5240783
DOI/URL:
Notes: Export Date: 4 May 2015 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Suzanne L Wolden
    560 Wolden